✔︎ 5 Memorial Day mattress-in-a-box deals: Save up to 60%
Memorial Day weekend is one of the best times of the year to buy a new mattress, and 2025's deals are bigger than ever. Whether you're furnishing a new bedroom or giving a guest room a well-needed upgrade, we've rounded up the top five Memorial Day mattress-in-a-box deals at some of the most popular brands. With deep discounts on comfortable sleepers, free bedding bundles and extended trials, what's not to love?
From plush memory foam to hybrid support, these deals deliver serious value and comfort. The best part about buying a mattress-in-a-box is that it arrives compressed in a compact box (or a bag, in Purple's case)—no need to coordinate with movers or delivery crews. Just unbox, unroll and let it expand!
Shop the best MDW sales at mattress brands like Casper, Purple, Leesa and more.
Top 5 Memorial Day 2025 mattress-in-a-box deals
Here are the best mattress-in-a-box deals for Memorial Day, based on current sales at top-rated mattress brands:
1. Casper Snow Mattress, Queen
2. DreamCloud Premier Hybrid Mattress, Queen
Memorial Day military discount: Extra 5% off any DreamCloud order
More: Get a DreamCloud mattress for $649 at this Memorial Day sale ⏰
3. Leesa Legend Hybrid Mattress, Queen
Sleep soundly this Memorial Day: Get up to $1,110 off Leesa mattresses
More: Get up to $799 off a new Purple mattress at this Memorial Day sale
5. Nectar Premier Memory Foam Mattress, Queen
More: Nectar hybrid and memory foam mattresses are up to 50% off at this huge Memorial Day sale
Are these mattresses easy to set up?
Yes! Mattress-in-a-box models arrive compressed and expand within hours of unboxing.
More: Parachute's dreamiest bedding sets, bath robes are 30% off at this Memorial Day sale
Are Memorial Day mattress deals better than other holiday sales?
Yes, Memorial Day is one of the best times of year to buy a mattress, often rivaling Black Friday and Labor Day in terms of discounts and special bundle offers.
When do Memorial Day mattress sales start and end?
Most mattress sales begin in early to mid-May and run through Memorial Day on Monday, May 26. Some brands extend deals into early June.
Memorial Day 2025 shopping guide: Best sales, deals, where to shop now
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Why Thermo Fischer Stock Is Rising Wednesday
Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported second-quarter 2025 adjusted earnings of $5.36 per share, beating the street view of $5.23. Quarterly sales of $10.86 billion increased 3% year-over-year, beating the analyst consensus estimate of $10.68 billion. Organic revenue growth was 2%. 'The agility of our organization, powered by the PPI Business System, allowed us to effectively adapt to current market conditions, actively manage our cost base and deliver strong operational results in the second quarter,' said Marc Casper, chairman, president and CEO of Thermo Fisher Scientific. The company said, 'PPI is helping us adjust our supply chains in the tariff environment and to actively manage our cost base.' Also Read: Management Change: Thermo Fisher Scientific announced Stephen Williamson, senior vice president and CFO, has decided to retire from the company, effective March 31, 2026. The company's board of directors appointed Jim Meyer, vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Guidance: During an earnings conference call, Thermo Fisher Scientific forecasts 2025 revenue of $43.6 billion-$44.2 billion, compared to prior guidance of $43.3 billion-$44.2 billion and the consensus of $43.71 billion. View more earnings on TMO The company expects adjusted earnings of $22.22-$22.84 per share, compared to prior guidance of $21.76-$22.84 and consensus of $22.33. The company adds that the U.S.-China tariff situation has improved significantly compared to prior assumptions. Last week, Thermo Fisher Scientific announced an expansion of its strategic partnership with Sanofi SA (NASDAQ:SNY) to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. Under the agreement, Thermo Fisher will acquire Sanofi's steriles manufacturing site in Ridgefield, New Jersey, and continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo Fisher will expand use of the site to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity. The Ridgefield site is a sterile fill-finish and packaging facility with over 200 employees who will join Thermo Fisher following the completion of the transaction. The transaction is expected to be completed in the second half of 2025. Upon completion of the transaction, Sanofi's Ridgefield facility will become part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment. Price Action: TMO stock is up 13.2% at $483.94 at the last check on Wednesday. Read Next:Photo: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? THERMO FISHER SCIENTIFIC (TMO): Free Stock Analysis Report This article Why Thermo Fischer Stock Is Rising Wednesday originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Business Wire
16 hours ago
- Business Wire
Thermo Fisher Scientific Reports Second Quarter 2025 Results
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025. Second quarter revenue grew 3% to $10.85 billion. Second quarter GAAP diluted earnings per share (EPS) grew 6% to $4.28. Second quarter adjusted EPS was $5.36. Delivered excellent operational performance in the quarter, reflecting active management of our company in the macroenvironment demonstrating the strength of our proven growth strategy and the power of the PPI Business System. Advanced our proven growth strategy, launching a range of high-impact innovation, strengthening our industry-leading commercial engine and deepening our trusted partner status with customers during the quarter to enable scientific breakthroughs and maximize customer productivity. Highlights include: Launched next-generation instruments including the Thermo Scientific™ Orbitrap™ Astral™ Zoom mass spectrometer, Thermo Scientific™ Orbitrap™ Excedion™ Pro mass spectrometer, and the Thermo Scientific™ Krios™ 5 Cryo-TEM. These instruments help researchers deepen the understanding of complex diseases, advance precision medicine, and enable the development of new therapies. We also expanded the DynaDrive™ single-use bioreactor portfolio for drug production to include a new first-of-its kind bench scale system, enabling meaningful workflow efficiencies and seamless scale-up from the bench to commercialization. The significant benefits of the Accelerator™ Drug Development solution were further validated by the publication of a Tufts Center study, which demonstrated that our integrated CDMO and CRO offerings can significantly shorten development timelines and deliver strong ROI for customers. Leveraged our PPI Business System to enable outstanding execution. PPI is helping us adjust our supply chains in the tariff environment and to actively manage our cost base. Reflecting our trusted partner status, shortly after the quarter ended, we expanded our strategic partnership with Sanofi to acquire its Ridgefield, New Jersey sterile fill-finish site, supporting Sanofi's portfolio of therapies and expanding U.S. capacity to meet growing demand from pharma and biotech customers. 'Our exceptional team continues to execute at a high level, enabling customer success while navigating the macroenvironment. The agility of our organization, powered by the PPI Business System, allowed us to effectively adapt to current market conditions, actively manage our cost base, and deliver strong operational results in the second quarter,' said Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher Scientific. Casper added: 'Our trusted partner status is resonating strongly with our customers allowing us to continue to drive market share gains and highlights our unique ability to enable their success in all market environments. We've made very good progress through the halfway point in the year, which positions us well to deliver on our 2025 commitments, while building an even brighter future for our company.' Second Quarter 2025 Revenue for the quarter grew 3% to $10.85 billion in 2025, versus $10.54 billion in the second quarter of 2024. Organic revenue growth was 2%. GAAP Earnings Results GAAP diluted EPS in the second quarter of 2025 was $4.28, versus $4.04 in the second quarter of 2024. GAAP operating income for the second quarter of 2025 was $1.83 billion, compared with $1.82 billion in the year-ago quarter. GAAP operating margin was 16.9%, compared with 17.3% in the second quarter of 2024. Non-GAAP Earnings Results Adjusted EPS in the second quarter of 2025 was $5.36, versus $5.37 in the second quarter of 2024. Adjusted operating income for the second quarter of 2025 was $2.38 billion, compared with $2.35 billion in the year-ago quarter. Adjusted operating margin was 21.9%, compared with 22.3% in the second quarter of 2024. Annual Guidance for 2025 The company will provide updated 2025 financial guidance during its earnings conference call this morning at 8:30 a.m. Eastern Time. Use of Non-GAAP Financial Measures Adjusted EPS, adjusted net income, adjusted operating income, adjusted operating margin, free cash flow, and organic revenue growth are non-GAAP measures that exclude certain items detailed after the tables that accompany this press release, under the heading 'Supplemental Information Regarding Non-GAAP Financial Measures.' The reconciliations of GAAP to non-GAAP financial measures are provided in the tables that accompany this press release. Note on Presentation Certain amounts and percentages reported within this press release are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding. Conference Call Thermo Fisher Scientific will hold its earnings conference call today, July 23, 2025, at 8:30 a.m. Eastern Time. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 523661. You may also listen to the call live on the 'Investors' section of our website, The earnings press release and related information can also be found in that section of our website under the heading 'Financials.' A replay of the call will be available under 'News, Events & Presentations' through October 21, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit Safe Harbor Statement The following constitutes a 'Safe Harbor' statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K and subsequent quarterly report on form 10-Q, which are on file with the SEC and available in the 'Investors' section of our website under the heading 'SEC Filings.' While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today. Three months ended June 28, % of June 29, % of (Dollars in millions except per share amounts) 2025 Revenues 2024 Revenues Revenues $ 10,855 $ 10,541 Costs and operating expenses: Cost of revenues (a) 6,378 58.8 % 6,106 57.9 % Selling, general and administrative expenses (b) 1,779 16.4 % 1,687 16.0 % Amortization of acquisition-related intangible assets 429 4.0 % 513 4.9 % Research and development expenses 352 3.2 % 339 3.2 % Restructuring and other costs (c) 82 0.8 % 77 0.7 % Total costs and operating expenses 9,021 83.1 % 8,722 82.7 % Operating income 1,834 16.9 % 1,820 17.3 % Interest income 297 295 Interest expense (404 ) (354 ) Other income/(expense) (d) (19 ) 5 Income before income taxes 1,709 1,765 Benefit from/(provision for) income taxes (e) (92 ) (128 ) Equity in earnings/(losses) of unconsolidated entities 2 (84 ) Net income 1,618 1,553 2 6 Net income attributable to Thermo Fisher Scientific Inc. $ 1,617 14.9 % $ 1,548 14.7 % Earnings per share attributable to Thermo Fisher Scientific Inc.: Basic $ 4.28 $ 4.05 Diluted $ 4.28 $ 4.04 Weighted average shares: Basic 378 382 Diluted 378 383 Reconciliation of adjusted operating income and adjusted operating margin GAAP operating income $ 1,834 16.9 % $ 1,820 17.3 % Cost of revenues adjustments (a) 10 0.1 % 1 0.0 % Selling, general and administrative expenses adjustments (b) 20 0.2 % (64 ) -0.6 % Restructuring and other costs (c) 82 0.8 % 77 0.7 % Amortization of acquisition-related intangible assets 429 4.0 % 513 4.9 % Adjusted operating income (non-GAAP measure) $ 2,375 21.9 % $ 2,347 22.3 % Reconciliation of adjusted net income GAAP net income attributable to Thermo Fisher Scientific Inc. $ 1,617 $ 1,548 Cost of revenues adjustments (a) 10 1 Selling, general and administrative expenses adjustments (b) 20 (64 ) Restructuring and other costs (c) 82 77 Amortization of acquisition-related intangible assets 429 513 Other income/expense adjustments (d) 5 — Income taxes adjustments (e) (133 ) (102 ) Equity in earnings/losses of unconsolidated entities (2 ) 84 Noncontrolling interests adjustments (f) (1 ) (1 ) Adjusted net income (non-GAAP measure) $ 2,026 $ 2,057 Reconciliation of adjusted earnings per share GAAP diluted EPS attributable to Thermo Fisher Scientific Inc. $ 4.28 $ 4.04 Cost of revenues adjustments (a) 0.03 0.00 Selling, general and administrative expenses adjustments (b) 0.05 (0.17 ) Restructuring and other costs (c) 0.22 0.20 Amortization of acquisition-related intangible assets 1.14 1.34 Other income/expense adjustments (d) 0.01 0.00 Income taxes adjustments (e) (0.35 ) (0.26 ) Equity in earnings/losses of unconsolidated entities (0.01 ) 0.22 Noncontrolling interests adjustments (f) 0.00 0.00 Adjusted EPS (non-GAAP measure) $ 5.36 $ 5.37 Reconciliation of free cash flow GAAP net cash provided by operating activities $ 1,399 $ 1,960 Purchases of property, plant and equipment (294 ) (301 ) Proceeds from sale of property, plant and equipment 1 15 Free cash flow (non-GAAP measure) $ 1,105 $ 1,674 Expand Business Segment Information Three months ended June 28, % of June 29, % of (Dollars in millions) 2025 Revenues 2024 Revenues Revenues Life Sciences Solutions $ 2,499 23.0 % $ 2,355 22.3 % Analytical Instruments 1,728 15.9 % 1,782 16.9 % Specialty Diagnostics 1,134 10.4 % 1,117 10.6 % Laboratory Products and Biopharma Services 5,995 55.2 % 5,758 54.6 % Eliminations (501 ) -4.6 % (470 ) -4.5 % Consolidated revenues $ 10,855 100.0 % $ 10,541 100.0 % Segment income and segment income margin Life Sciences Solutions $ 919 36.8 % $ 865 36.7 % Analytical Instruments 325 18.8 % 439 24.6 % Specialty Diagnostics 306 27.0 % 299 26.7 % Laboratory Products and Biopharma Services 825 13.8 % 745 12.9 % Subtotal reportable segments 2,375 21.9 % 2,347 22.3 % Cost of revenues adjustments (a) (10 ) -0.1 % (1 ) 0.0 % Selling, general and administrative expenses adjustments (b) (20 ) -0.2 % 64 0.6 % Restructuring and other costs (c) (82 ) -0.8 % (77 ) -0.7 % Amortization of acquisition-related intangible assets (429 ) -4.0 % (513 ) -4.9 % Consolidated GAAP operating income $ 1,834 16.9 % $ 1,820 17.3 % Expand (a) Adjusted results in 2025 exclude $5 of accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations and $5 of charges for the sale of inventory revalued at the date of acquisition. Adjusted results in 2024 exclude charges for inventory write-downs associated with large-scale abandonment of product lines. (b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions and charges/credits for changes in estimates of contingent acquisition consideration. (c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges/credits for pre-acquisition litigation and other matters, and abandoned facility and other expenses of headcount reductions and real estate consolidations. (d) Adjusted results exclude net gains/losses on investments. Adjusted results in 2025 exclude $5 of charges for settlement of pension plans. (e) Adjusted results exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes and the tax impacts from audit settlements. Note: Consolidated depreciation expense is $256 and $276 in 2025 and 2024, respectively. Expand Note: For more information related to non-GAAP financial measures, refer to the section titled 'Supplemental Information Regarding Non-GAAP Financial Measures' of this release. Expand Condensed Consolidated Statements of Income (unaudited) Six months ended June 28, % of June 29, % of (Dollars in millions except per share amounts) 2025 Revenues 2024 Revenues Revenues $ 21,219 $ 20,886 Costs and operating expenses: Cost of revenues (a) 12,435 58.6 % 12,146 58.2 % Selling, general and administrative expenses (b) 3,500 16.5 % 3,417 16.4 % Amortization of acquisition-related intangible assets 859 4.0 % 1,065 5.1 % Research and development expenses 695 3.3 % 670 3.2 % Restructuring and other costs (c) 180 0.9 % 106 0.5 % Total costs and operating expenses 17,668 83.3 % 17,404 83.3 % Operating income 3,551 16.7 % 3,483 16.7 % Interest income 501 574 Interest expense (707 ) (717 ) Other income/(expense) (d) (16 ) 14 Income before income taxes 3,329 3,354 Benefit from/(provision for) income taxes (e) (187 ) (408 ) Equity in earnings/(losses) of unconsolidated entities (12 ) (61 ) Net income 3,130 2,885 Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest (f) 6 9 Net income attributable to Thermo Fisher Scientific Inc. $ 3,124 14.7 % $ 2,875 13.8 % Earnings per share attributable to Thermo Fisher Scientific Inc.: Basic $ 8.27 $ 7.53 Diluted $ 8.26 $ 7.50 Weighted average shares: Basic 378 382 Diluted 378 383 Reconciliation of adjusted operating income and adjusted operating margin GAAP operating income $ 3,551 16.7 % $ 3,483 16.7 % Cost of revenues adjustments (a) 21 0.1 % 17 0.1 % Selling, general and administrative expenses adjustments (b) 34 0.2 % (45 ) -0.2 % Restructuring and other costs (c) 180 0.9 % 106 0.5 % Amortization of acquisition-related intangible assets 859 4.0 % 1,065 5.1 % Adjusted operating income (non-GAAP measure) $ 4,644 21.9 % $ 4,625 22.1 % Reconciliation of adjusted net income GAAP net income attributable to Thermo Fisher Scientific Inc. $ 3,124 $ 2,875 Cost of revenues adjustments (a) 21 17 Selling, general and administrative expenses adjustments (b) 34 (45 ) Restructuring and other costs (c) 180 106 Amortization of acquisition-related intangible assets 859 1,065 Other income/expense adjustments (d) 4 (11 ) Income taxes adjustments (e) (256 ) (51 ) Equity in earnings/losses of unconsolidated entities 12 61 Noncontrolling interests adjustments (f) (1 ) (1 ) Adjusted net income (non-GAAP measure) $ 3,976 $ 4,016 Reconciliation of adjusted earnings per share GAAP diluted EPS attributable to Thermo Fisher Scientific Inc. $ 8.26 $ 7.50 Cost of revenues adjustments (a) 0.06 0.04 Selling, general and administrative expenses adjustments (b) 0.09 (0.12 ) Restructuring and other costs (c) 0.48 0.28 Amortization of acquisition-related intangible assets 2.27 2.78 Other income/expense adjustments (d) 0.01 (0.03 ) Income taxes adjustments (e) (0.68 ) (0.13 ) Equity in earnings/losses of unconsolidated entities 0.03 0.16 Noncontrolling interests adjustments (f) 0.00 0.00 Adjusted EPS (non-GAAP measure) $ 10.51 $ 10.47 Reconciliation of free cash flow GAAP net cash provided by operating activities $ 2,122 $ 3,211 Purchases of property, plant and equipment (656 ) (648 ) Proceeds from sale of property, plant and equipment 13 20 Free cash flow (non-GAAP measure) $ 1,479 $ 2,583 Expand Business Segment Information Six months ended June 28, % of June 29, % of (Dollars in millions) 2025 Revenues 2024 Revenues Revenues Life Sciences Solutions $ 4,840 22.8 % $ 4,640 22.2 % Analytical Instruments 3,446 16.2 % 3,469 16.6 % Specialty Diagnostics 2,282 10.8 % 2,227 10.7 % Laboratory Products and Biopharma Services 11,635 54.8 % 11,480 55.0 % Eliminations (983 ) -4.6 % (930 ) -4.5 % Consolidated revenues $ 21,219 100.0 % $ 20,886 100.0 % Segment income and segment income margin Life Sciences Solutions $ 1,753 36.2 % $ 1,705 36.7 % Analytical Instruments 724 21.0 % 838 24.2 % Specialty Diagnostics 610 26.7 % 593 26.6 % Laboratory Products and Biopharma Services 1,557 13.4 % 1,489 13.0 % Subtotal reportable segments 4,644 21.9 % 4,625 22.1 % Cost of revenues adjustments (a) (21 ) -0.1 % (17 ) -0.1 % Selling, general and administrative expenses adjustments (b) (34 ) -0.2 % 45 0.2 % Restructuring and other costs (c) (180 ) -0.9 % (106 ) -0.5 % Amortization of acquisition-related intangible assets (859 ) -4.0 % (1,065 ) -5.1 % Consolidated GAAP operating income $ 3,551 16.7 % $ 3,483 16.7 % Expand (a) Adjusted results exclude accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations. Adjusted results in 2025 exclude $10 of charges for the sale of inventory revalued at the date of acquisition. Adjusted results in 2024 also exclude $13 of charges for inventory write-downs associated with large-scale abandonment of product lines. (b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions and charges/credits for changes in estimates of contingent acquisition consideration. (c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges for pre-acquisition litigation and other matters, net gains/losses on the sale of real estate, and abandoned facility and other expenses of headcount reductions and real estate consolidations. (d) Adjusted results exclude net gains/losses on investments. Adjusted results in 2025 exclude $5 of charges for settlement of pension plans. (e) Adjusted results exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes and the tax impacts from audit settlements. Notes: Consolidated depreciation expense is $532 and $562 in 2025 and 2024, respectively. For more information related to non-GAAP financial measures, refer to the section titled 'Supplemental Information Regarding Non-GAAP Financial Measures' of this release. Expand Note: For more information related to non-GAAP financial measures, refer to the section titled 'Supplemental Information Regarding Non-GAAP Financial Measures' of this release. Expand Condensed Consolidated Balance Sheets (unaudited) June 28, December 31, (In millions) 2025 2024 Assets Current assets: Cash and cash equivalents $ 4,576 $ 4,009 Short-term investments 1,814 1,561 Accounts receivable, net 8,594 8,191 Inventories 5,559 4,978 Other current assets 4,040 3,399 Total current assets 24,584 22,137 Property, plant and equipment, net 9,635 9,306 Acquisition-related intangible assets, net 15,148 15,533 Other assets 4,615 4,492 Goodwill 47,249 45,853 Total assets $ 101,230 $ 97,321 Liabilities, redeemable noncontrolling interest and equity Current liabilities: Short-term obligations and current maturities of long-term obligations $ 2,214 $ 2,214 Other current liabilities 10,504 11,118 Total current liabilities 12,718 13,332 Other long-term liabilities 4,894 5,257 Long-term obligations 33,015 29,061 Redeemable noncontrolling interest 126 120 Total equity 50,476 49,551 Total liabilities, redeemable noncontrolling interest and equity $ 101,230 $ 97,321 Expand Condensed Consolidated Statements of Cash Flows (unaudited) Six months ended June 28, June 29, (In millions) 2025 2024 Operating activities Net income $ 3,130 $ 2,885 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 1,391 1,626 Change in deferred income taxes (601 ) (607 ) Other non-cash expenses, net 354 311 Changes in assets and liabilities, excluding the effects of acquisitions (2,151 ) (1,003 ) Net cash provided by operating activities 2,122 3,211 Investing activities Purchases of property, plant and equipment (656 ) (648 ) Proceeds from sale of property, plant and equipment 13 20 Proceeds from cross-currency interest rate swap interest settlements 134 111 Purchases of investments (311 ) (1,778 ) Other investing activities, net 6 12 Net cash used in investing activities (815 ) (2,283 ) Financing activities Net proceeds from issuance of debt 2,840 1,204 Repayment of debt (1,625 ) — Purchases of company common stock (2,000 ) (3,000 ) Dividends paid (311 ) (284 ) Other financing activities, net 3 145 Net cash used in financing activities (1,093 ) (1,936 ) Exchange rate effect on cash 348 7 Increase (decrease) in cash, cash equivalents and restricted cash 563 (1,000 ) Cash, cash equivalents and restricted cash at beginning of period 4,040 8,097 Cash, cash equivalents and restricted cash at end of period $ 4,603 $ 7,097 Free cash flow (non-GAAP measure) $ 1,479 $ 2,583 Expand Supplemental Information Regarding Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of acquisitions/divestitures and the effects of currency translation. We report these measures because Thermo Fisher management believes that in order to understand the company's short-term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures, and/or foreign currency translation on revenues. Thermo Fisher management uses these measures to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods. We report adjusted operating income, adjusted operating margin, adjusted net income, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company's core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable: Certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction/acquisition-related costs, including changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs. Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities are not indicative of our normal operating costs. Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies. The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods. We report free cash flow, which is operating cash flow less net capital expenditures, to provide a view of the continuing operations' ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure. Thermo Fisher Scientific does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The timing and amount of these items are uncertain and could be material to Thermo Fisher Scientific's results computed in accordance with GAAP. The non-GAAP financial measures of Thermo Fisher Scientific's results of operations and cash flows included in this press release are not meant to be considered superior to or a substitute for Thermo Fisher Scientific's results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the tables above.
Forbes
a day ago
- Forbes
Nectar Mattress Sale: Shop Editor-Tested Beds At Up To 62% Off
While there's almost always a Nectar mattress sale happening, the current discounts match ones we saw during Memorial Day and the 4th of July. Right now you can save up to 50% on beds and up to 66% on bundles during the Summer Spectacular event—on par with the lowest prices we've seen so far this year. The queen size of our pick for the best memory foam mattress overall, the Nectar Premier, is on sale for under $1,000—a great price for a luxury model. Save up to 50% on a new mattress and up to 66% on bundles during Nectar's mattress sale. ILLUSTRATION: FORBES / PHOTO: RETAILER All four of Nectar's mattress models—the Classic, Premier, Luxe and Ultra—have recently been revamped. The 2025 update contributed to a price increase, but its current sale prices are in line with what we've seen over recent holiday weekends. Below, we've outlined the advantages of each model, almost all of which occupy top spots in our mattress shopping guides after being tested firsthand by our editors. For more deals on our top mattress picks of 2025, check out our roundup of the best mattress sales this month. Nectar Mattress Sale: Best Offers At A Glance Nectar Mattress Sale: Editor Recommendations Our Top Choice For The Best Memory Foam Mattress Under $1,000 Nectar Nectar Classic Mattress (Queen) Shop At Nectar Nectar's entry-level model provides comfort and support without breaking the bank. The Classic bed offers excellent motion isolation and pressure relief as well as cooling properties, but it costs almost half the price of the brand's Luxe model—which is why it's our editors' pick for the best memory foam mattress under $1,000. If you want a bit more support, consider the hybrid version of this mattress, which is marked down to $799 (formerly $1,490) right now. The Best Memory Foam Mattress Overall, According To Our Tests Nectar The Nectar Premier Mattress (Queen) Shop At Nectar The Nectar Premier falls right between Nectar's Classic and Luxe models in terms of design and features—and it's our recommendation for the best memory foam mattress overall. The Premier's quilted cover is designed to help wick away moisture and regulate temperature while still providing bounce and support. The design also delivers solid motion isolation, a major perk for those who share a bed with restless partners. Our Pick For The Best Value Cooling Mattress Nectar Nectar Luxe Mattress (Queen) Shop At Nectar The Nectar Luxe's 14 inches of layered material is designed to support your joints and relieve pressure, while its cooling copper cover dissipates heat and wicks away moisture. The mattress is ideal for side sleepers, couples and hot sleepers—and you can save hundreds of dollars if you get it during Nectar's current mattress sale. The hybrid model, our current top pick for the best value cooling mattress on the market, offers a combination of memory foam and individually wrapped springs for added breathability and support; just keep in mind that the price tag is slightly higher than the memory foam version. A Super-Cushy Mattress For Side Sleepers Nectar Sleep Nectar Ultra Mattress (Queen) Shop At Nectar The Nectar Ultra is the brand's softest and highest-end model, and you can purchase it as a foam mattress or a hybrid version for an extra $200. When our sleep editors tested the memory foam model, they noted it has a super-cushy, dense feel that's reminiscent of a Tempur-Pedic mattress. Even the hybrid model, which was springier than the memory foam, offered a good deal of that 'sinking-in' feeling. Because of this, we recommend the Nectar Ultra for those who prefer or would benefit from a soft mattress, including side sleepers and back sleepers under 250 pounds. The Hybrid Version Of Nectar's Classic Design Nectar Nectar Classic Hybrid Mattress Shop at Nectar If you can't decide between a memory foam or innerspring mattress, this hybrid design gives you the best of both worlds: contouring memory foam combined with extra support, airflow and motion isolation from its innerspring coils. The 12-inch design also has a cooling top layer with an antimicrobial treatment that keeps your sleeping surface clean and cool to the touch. This model is currently available for 53% off. A Firm Yet Plush Option For All Types Of Sleepers Nectar Nectar Premier Hybrid Mattress Shop At Nectar Nectar's most popular hybrid mattress, the Premier Hybrid offers double the pressure relief and more enhanced cooling features compared to the Classic Hybrid. Designed to support all types of sleepers, its individually-wrapped coils bring sturdy support, reliable motion control and healthy airflow, creating a feel that's both firm and plush. Our tester reported reduced hip pain and noted that the cooling top layer effectively regulated their temperature for a more restful night's sleep. An Excellent Adjustable Bed And Mattress Combo Nectar Nectar Premier Adjustable Bundle (Queen) Shop At Nectar If you're considering upgrading your bed frame to an adjustable one, check out this deal on the Nectar Premier Adjustable Bundle. Not only does it feature the brand's highly rated adjustable bed frame, but it also offers your choice of a memory foam or hybrid mattress. The memory foam option is ideal for back pain relief, while the hybrid is designed to keep hot sleepers comfortable. As for the adjustable base, it provides independent head and foot adjustability, anti-snore presets, a whisper-quiet two-zone massage feature and adjustable height. A Minimalistic Bed Frame And Mattress Bundle Nectar Nectar Bamboo Bed And Mattress Bundle (Queen) Shop At Nectar This solid bamboo bed frame is a minimalist's dream, thanks to its clean lines and uncluttered silhouette. Bamboo is lightweight yet durable, and the interlocking joints mean you don't need to fuss with screws and nails when putting this together. (The assembly is tool-free and easy to do, even if you live alone.) Choose a walnut or natural wood finish, and complete your bundle with one of Nectar's mattresses. A Versatile Bed Frame With A Mattress Of Your Choice Nectar Nectar Foundation Bundle Shop At Nectar If you're looking for a versatile bed frame and mattress combination, Nectar's Foundation Bundle delivers both. The bundle includes any Nectar mattress of your choice, plus the brand's Foundation frame, which can function as a standalone platform bed, pair with a headboard, or be used without legs as a supportive box spring. It also features upholstered corners and rounded feet to prevent any bumps and bruises throughout the day or night. An Adjustable, Programmable Frame With Custom Elevation nectar Nectar Premier Adjustable Bed Frame (Queen) Shop At Nectar If you already own a Nectar mattress and want to upgrade your frame to an adjustable one, you don't have to buy a bundle to get a steep discount. The Premier Adjustable Frame is now available for $749, over 50% off its original price. Not only will you get independent head and foot isolation for under $800, but you'll also have app and remote control, one-touch recline and zero-gravity settings (among others), three massage intensities and four built-in USB ports. Plus, the assembly is tool-free. A Sturdy, Upholstered Frame With A Tufted Headboard nectar Nectar Bed Frame With Headboard Shop At Nectar While Nectar is only advertising deals on mattresses and bundles during its Summer Spectacular event, some of its sturdy, contemporary-style bed frames are also on sale. If the adjustable frame mentioned above has too many frills, you'll appreciate the more simple, timeless design of this upholstered frame, which is 43% off. It features a classic button-tufted headboard and can accommodate up to 700 pounds. It's available in both Grey and Linen and is built with six 8-inch legs, and because it uses sturdy wooden slats, you won't need a box spring. This Highly-Rated, Minimalist Frame Nectar Nectar Mattress Foundation Steel Frame (Queen) Shop At Nectar If you're looking for a sleek, minimalist design, this steel frame comes highly rated with over 3,000 five-star reviews. It has a wood slat foundation, a durable steel frame and includes a two-year warranty. The versatile design can be used alone for a sleek, understated look or paired with a statement piece headboard. You can also remove the legs for a low-profile, platform look or stack it on an existing frame as a supportive boxspring. During the sale, you can grab this simple design for 21% off. Why Trust Forbes Vetted The Forbes Vetted editorial team has extensive experience testing, researching and reviewing the best products on the market. Our mattress shopping guides are based on expert medical advice, hundreds of hours of research and extensive firsthand testing. Jordan Thomas, the author of this story, is Forbes Vetted's assistant deals editor. She has over five years of experience writing in the e-commerce space and was previously a deals writer at Wirecutter. She routinely researches deals and savings events—including mattress sales—to find the best offers available. Our mattress and sleep content is overseen by senior mattress and sleep editor Bridget Chapman, who has a decade of experience as a journalist and holds a sleep science coach certification, which she leans on to weed out false advertising claims and uncover real benefits in the online mattress industry. Mattress and sleep editor McKenzie Dillon is also a certified sleep science coach and prolific mattress tester with five years of experience. In addition to their years of expertise and sleep science coaching certifications, Chapman and Dillon, along with the rest of the Forbes Vetted sleep team, have rigorously tested and re-tested over 120 of mattresses using carefully crafted methodology. Do Nectar Mattresses Ever Go On Sale? Yes, Nectar frequently offers promotions on its mattresses, bed frames and bedding throughout the year. That said, the highest discounts usually fall around holiday weekends or major shopping events, like Black Friday, Cyber Monday, President's Day, Memorial Day and Labor Day. We've seen consistent markdowns during these windows—specifically, 50% off mattresses and up to 66% off bundles. The current summer sale is offering deals on par with these peak shopping times, making now as good a time as any to purchase a new bed. What Is The Lifespan Of A Nectar Mattress? How long a mattress lasts depends on several factors, such as body weight, sleeping positions and overall care. Typically, Nectar's all-foam models remain in good condition for anywhere between 8 to 10 years, while the hybrid models can last up to 12 years. Nectar offers a lifetime warranty that covers material or manufacturing defects—but this doesn't include normal wear and tear or damage caused directly by the owner.
